



Prothena Corporation plc  
 Investor Relations Department  
 331 Oyster Point Blvd  
 South San Francisco, CA 94080  
 United States

[Visit IR website](#)   
[Sign-up for Email alerts](#)

**NASDAQ: PRTA**

Last Trade:	39.23
Trade Time:	12:11 PM ET Jan 19, 2018
Change:	-0.46  (-1.159%)
Day Range	39.10 - 39.93
52-Week Range	34.85 - 70.00
Volume	124,001

Stock information is provided by eSignal, stock charts provided by EDGAR Online. Stock data is delayed approximately 20 minutes.

**Company Profile**

Prothena Corporation plc (Nasdaq: PRTA) is a late-stage clinical biotechnology company focused on the discovery, development and commercialization of novel protein immunotherapies for the potential treatment of diseases that involve amyloid or cell adhesion. Our antibody-based product candidates target a number of potential indications including AL amyloidosis (NEOD001), Parkinson's disease and other related synucleinopathies (PRX002), and ATTR amyloidosis (PRX004).

... [\(more\)](#)

**Stock Performance**



**Press Releases** [\[ View all \]](#)

- Jan 3, 2018*  
[Prothena to Participate in the 36th Annual J.P. Morgan Healthcare Conference](#)
- Nov 22, 2017*  
[Prothena to Participate in the Evercore ISI Biopharma Catalyst/Deep Dive Conference](#)
- Nov 16, 2017*  
[Prothena Highlights Breadth of Novel Pipeline at R&D Day](#)
- Nov 7, 2017*  
[Prothena Reports Third Quarter 2017 Financial Results and Provides R&D Update](#)
- Nov 1, 2017*  
[Prothena to Participate in the Credit Suisse 26th Annual Healthcare Conference](#)

**Financials** [\[ View all \]](#)

- [Third Quarter Financial Results](#)
- Feb 27, 2017*  
[Annual Report \(10-K\)](#)
- Mar 31, 2017*  
[Proxy Statement \(DEF 14A\)](#)
- Nov 7, 2017*  
[Quarterly Report \(10-Q\)](#)
- Aug 9, 2017*  
[Quarterly Report \(10-Q\)](#)
- May 9, 2017*  
[Quarterly Report \(10-Q\)](#)